RedChip Companies
|
Weekly Newsletter
|
|
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
|
Aridis Pharmaceuticals (Nasdaq: ARDS), a biopharmaceutical company, announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients. Including this funding, the CF Foundation has provided a total of $12.5 million in support. Enrollment for a Phase 2a study of AR-501 in CF patients was completed in November 2022. The Company anticipates reporting top-line results from its Phase 2a study in the first quarter of 2023.
For more information, visit www.aridispharma.com
|
Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products
Sharps Technology (Nasdaq: STSS), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announced the signing of a distribution agreement with its partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.
|
Digital Ally announced Spin-off Creates Kustom Entertainment to Join Together its New Entertainment and Ticketing Businesses
Digital Ally (Nasdaq: DGLY) announced plans to complete a corporate spin-off of its newly formed division, Kustom Entertainment, in the first half of 2023. Kustom Entertainment will focus on live event and concert production to accompany TicketSmarter’s ability to offer primary and secondary ticketing options.
|
|
|
Inspira™ Technologies Signs Agreement to Conduct Clinical Study of HYLA™ Blood Sensor
Inspira Technologies (Nasdaq: IINN), a groundbreaking respiratory support technology company, signed an agreement to conduct a clinical study of the HYLA blood sensor with Sheba Medical Center in Israel. The clinical study, expected to commence in the first quarter of 2023, will be performed in an operating room setting in patients undergoing open heart surgery using a cardiopulmonary bypass machine (CPB). The study objective is to further evaluate the HYLA blood sensor's capabilities to measure blood gases in a non-invasive and continuous manner. The study results are expected to have a significant contribution to the product's development.
|
KWESST Delivers Phantom(TM) Electronic Decoy to General Dynamics Land Systems - Canada for U.S. Marine Corps Advanced Reconnaissance Vehicle Military Program
KWESST Micro Systems (Nasdaq: KWE) announced that it has delivered the first Phantom(TM) system to General Dynamics Land Systems ("GDLS-C") as part of GDLS-C's bid for several hundred next-generation reconnaissance vehicles for the U.S. Marine Corps. The Phantom(TM) capability is designed to meet evolving Electro-Magnetic Spectrum Operations ("EMSO") tactics, techniques, and procedures to be employed by reconnaissance operators in a contested Radio Frequency ("RF") environment, a feature of the modern battlefield as seen in conflict zones like Ukraine and elsewhere.
|
|
|
Upcoming Events |
|
|
|
NASDAQ: NTRB - Nutriband |
4:15pm Eastern |
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies, benefitting patients, physicians, and payers. |
|
|
|
|
NASDAQ: SVFD - Save Foods |
4:15pm Eastern |
Save Foods Inc and its Israeli subsidiary Save Foods Ltd are innovative, dynamic companies dedicated to delivering integrated eco-friendly solutions for improved safety, freshness and quality, every step of the way from field to fork. |
|
|
|
|
NASDAQ: MDGS - Medigus Ltd. |
11:00am Eastern |
An Israeli technology company, Medigus is focused on building innovative growth partnerships, primarily in advanced medical solutions, digital commerce, and electric vehicle (EV) markets. |
|
|
Archive Events |
|
|
|
NASDAQ: UNCY - Unicycive Therapeutics Inc. |
Meeting Duration 30 minutes |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. |
|
|
|
|
NASDAQ: ASPI - ASP Isotopes |
Meeting Duration 30 minutes |
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. |
|
|
|
|
NASDAQ: SYTA - Siyata Mobile |
Meeting Duration 34 minutes |
Siyata Mobile (Siyata or the Company) is a leading developer and distributor of technologically advanced rugged smartphones, in-vehicle mounted IoT cellular communications devices, and cellular signal boosters for global first responders and enterprise customers based on Push-to-Talk Over Cellular (PoC) technology. |
|
|
|
|
NYSE American: CANF - Can-Fite BioPharma Ltd. |
Meeting Duration 27 minutes |
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. |
|
|
|
|
NASDAQ : AMAO - Royalty Management Corporation |
Meeting Duration 35 minutes |
Royalty Management Corporation is a royalty company building shareholder value to benefit both our shareholders and communities by acquiring and developing high value assets in a sustainable market environment. |
|
|
Lesson of the Week
Microcap pros make millions by buying before the crowd.
|
|
|
RedChip TV |
MidSouth Week in Review
Inflation slowed to 7.1% vs. 7.7% the previous month.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
|
© 2022 RedChip , All rights reserved
|
|
|
|
|
|